Drug Enforcement Administration reduces opioid production in USA

09 November 2016
Drug Enforcement Administration reduces opioid production in USA

The Drug Enforcement Administration has recently announced that the amount of most opioid medications that can be manufactured for sale and research in the US in 2017 will be reduced by 25% or more from this year’s quota. The federal agency sets annual quotas to regulate the production of controlled substances in US.

The DEA’s new quotas for 2017 reduce the amount of several addictive prescription painkillers including oxycodone, hydrocodone, fentanyl, hydromorphone and morphine. Deaths from opioid overdoses have increased sharply in the past two decades, and overdose deaths from all drugs claim about 80 lives a day in the US, according to data from 2014.

According to the DEA, the drop in next year’s quotas is due to a decreased demand for opioid medications as more physicians become informed about the dangers of overprescribing pain medication.

The DEA announcement reverses years of permitting an increased flow of these drugs throughout the country, although levels remain high compared with the years before the opioid crisis. However opioid expert, Dr Andrew Kolodny, has criticised the announcement saying “this would have been helpful if it had happened 10 to 15 years ago when consumption was still rising and rising quickly”.

Randox Toxicology offer a complete range of drug screening solutions and have recently developed the most extensive biochip array, DoA ULTRA. The 20 test panel can simultaneously detect oxycodone, hydrocodone, fentanyl, hydromorphone and morphine among others.

Read more at The Guardian.

UK: +44 (0)28 9442 2413
USA: +1 304 728 2890